Cosette appeals loss over exit from $672M Mayne Pharma merger
M&A 2025-11-10 3:17 pm By Cat Fredenburgh
Please login to bookmark Close

Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au